RecruitingPhase 4NCT04669717

Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies

Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month, Parallel-group, Clinical Trial.


Sponsor

University of Geneva, Switzerland

Enrollment

45 participants

Start Date

Sep 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation. In the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

  • Informed Consent as documented by signature
  • Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy
  • Presence of at least 30% of the teeth in the mouth with PD\>6mm and BOP

Exclusion Criteria10

  • Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, human immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation, or immunosuppressive therapy)
  • Pregnancy or lactation
  • Persons who had taken AB within the previous 2 months
  • Persons who are taking nonsteroidal anti-inflammatory drugs
  • Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides
  • Previous periodontal therapy the last 1 year
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant
  • Participants not willing to attend regular dental maintenance visits and follow-up evaluations
  • Participation in another study with investigational drug within the 30 days preceding and during the present study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days

Non-surgical periodontal therapy and radnomly administration of the antibiotics

DRUG3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days

Non-surgical periodontal therapy and radnomly administration of the antibiotics

DRUG1/d 500 mg Azithromycine Pfizer for 3 days

Non-surgical periodontal therapy and radnomly administration of the antibiotics


Locations(1)

University of Geneva, University Clinics of Dental Medicine

Geneva, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04669717


Related Trials